Skip to main content
Premium Trial:

Request an Annual Quote

LABSCO Distributing Response Biomedical's Cardiovascular Test Products in US

NEW YORK (GenomeWeb News) – Response Biomedical announced on Thursday a US distribution deal covering its cardiovascular portfolio of Ramp products.

Under the agreement, Louisville, Ky.-based Laboratory Supply Company (LABSCO) will distribute Ramp products in the US exclusively to hospital with less than 150 beds. The agreement is between Response Biomed's newly formed, wholly owned US subsidiary Response Point of Care and LABSCO for an initial period of three years, renewable upon mutual agreement.

Additional terms of the deal were not disclosed.

Privately held LABSCO distributes clinical laboratory products in the US.

LABSCO will initially market Response's cardiovascular POC tests panels on the Ramp Reader in all settings and on the Ramp 200 reader in laboratory settings. Response said it will continue to make the cardiovascular POC test panel on the Ramp 200 and Ramp Reader available outside the US. It also will continue marketing the Ramp Flu A+B Assay and Ramp RSV Assay on the Ramp 200 globally where approved by regulators.

The Ramp platform is a portable scanning fluorescence quantitative analysis platform for near-patient testing.

"This is a very important agreement for Response as it marks a significant step into the US market for POCT in the cardiovascular arena, which is one of the largest markets in the world," Tim Shannon, senior vice president of worldwide sales and marketing for Vancouver, British Columbia-based Response Biomed, said in a statement. "We believe that LABSCO has the experience and reputation to maximize our efforts to gain traction and to help us penetrate a market that we believe will greatly enhance our growth in the near term and beyond."

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.